
Basilea nominates Domenico Scala as new chairman
pharmafile | March 15, 2016 | Appointment | Business Services, Manufacturing and Production |Â Â Basilea, Chariman, Executive appointmentÂ
Switzerland-based Basilea Pharmaceutica on Tuesday nominated Domenico Scala as the new chairman of the board.
The current Chairman, Martin Nicklasson will not stand for re-election at the Annual General Meeting scheduled for April 21, 2016, the company said in a statement. However, Mr Nicklasson, who has been Chairman since 2013, will stand for re-election as a board member.
Mr Scala has been the vice-chairman at Basilea since 2011. From 2007 to 2011, he was president and chief executive at Nobel Biocare and served as the Chief Financial Officer at Syngenta International from 2003 to 2007.
Anjali Shukla
Related Content
FDA approves new anti-fungal treatment
The FDA has given the OK to Astellas and Basilea for their new treatment in …
GSK pays £146 million for eczema drug
GlaxoSmithKline has paid £146 million for Basilea Pharmaceutica’s dermatology drug Toctino. Toctino (alitretinoin) is approved …
Zeftera problems weigh down Basilea
Specialist Swiss pharma company Basilea has announced a doubling of its revenues in 2009, thanks …






